ADAR Trademark

Trademark Overview


On Saturday, May 7, 2022, a trademark application was filed for ADAR with the United States Patent and Trademark Office. The USPTO has given the ADAR trademark a serial number of 79346652. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, October 11, 2023. This trademark is owned by EDIGENE INC.. The ADAR trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Cells for medical or clinical use; pharmaceutical preparations in the nature of genetically modified therapeutic pharmaceuticals for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations in the nature of genetically modified therapeutic pharmaceuticals, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations in the nature of biological tissue grafts; diagnostic reagents for medicinal use

Medical and scientific research in the field of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; medical and scientific research information in the field of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; pharmaceutical research and development; pharmaceutical research services; providing medical and scientific research information in the fields of pharmaceuticals and genetics
adar

General Information


Serial Number79346652
Word MarkADAR
Filing DateSaturday, May 7, 2022
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, October 11, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesCells for medical or clinical use; pharmaceutical preparations in the nature of genetically modified therapeutic pharmaceuticals for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations in the nature of genetically modified therapeutic pharmaceuticals, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations in the nature of biological tissue grafts; diagnostic reagents for medicinal use
Goods and ServicesMedical and scientific research in the field of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; medical and scientific research information in the field of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; pharmaceutical research and development; pharmaceutical research services; providing medical and scientific research information in the fields of pharmaceuticals and genetics

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 5, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 5, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEDIGENE INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCN

Trademark Events


Event DateEvent Description
Thursday, August 4, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, August 5, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 9, 2022APPLICATION FILING RECEIPT MAILED
Sunday, December 18, 2022LETTER OF PROTEST EVIDENCE FORWARDED
Thursday, February 2, 2023ASSIGNED TO EXAMINER
Monday, February 6, 2023LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
Monday, February 6, 2023NON-FINAL ACTION WRITTEN
Tuesday, February 7, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, March 29, 2023REFUSAL PROCESSED BY MPU
Wednesday, March 29, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, April 20, 2023REFUSAL PROCESSED BY IB
Wednesday, October 11, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, October 11, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Wednesday, October 11, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Wednesday, January 10, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, January 10, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, January 29, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, October 15, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, October 23, 2024FINAL DISPOSITION NOTICE SENT TO IB